Signaturefd LLC Grows Stock Position in Genmab A/S (NASDAQ:GMAB)

Signaturefd LLC increased its position in shares of Genmab A/S (NASDAQ:GMAB) by 32.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,900 shares of the company’s stock after purchasing an additional 1,920 shares during the quarter. Signaturefd LLC’s holdings in Genmab A/S were worth $193,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its position in Genmab A/S by 360.5% during the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock worth $882,000 after acquiring an additional 23,094 shares during the last quarter. Capital International Investors boosted its holdings in shares of Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after purchasing an additional 315,355 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in shares of Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after purchasing an additional 45,376 shares in the last quarter. Choreo LLC acquired a new stake in shares of Genmab A/S in the second quarter valued at approximately $776,000. Finally, Renaissance Technologies LLC lifted its position in Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after buying an additional 103,859 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on GMAB shares. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday, October 16th. Truist Financial reduced their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Trading Up 1.3 %

Shares of NASDAQ GMAB opened at $23.12 on Monday. The stock has a fifty day simple moving average of $25.34 and a 200-day simple moving average of $26.81. Genmab A/S has a twelve month low of $22.39 and a twelve month high of $32.89. The stock has a market capitalization of $15.30 billion, a PE ratio of 19.11, a PEG ratio of 0.68 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). The business had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. On average, equities analysts predict that Genmab A/S will post 1.29 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.